The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence.
The requirement for multiple mutations for protease inhibitor (PI) resistance necessitates a better understanding of the molecular basis of resistance development. The novel bioinformatics resistance determination approach presented here elaborates on genetic profiles observed in clinical human immunodeficiency virus type 1 (HIV-1) isolates. Synthetic protease sequences were cloned in a wild-type HIV-1 background to generate a large number of close variants, covering 69 mutation clusters between multi-PI-resistant viruses and their corresponding genetically closely related, but PI-susceptible, counterparts. The vast number of mutants generated facilitates a profound and broad analysis of the influence of the background on the effect of individual PI resistance-associated mutations (PI-RAMs) on PI susceptibility. Within a set of viruses, all PI-RAMs that differed between susceptible and resistant viruses were varied while maintaining the background sequence from the resistant virus. The PI darunavir was used to evaluate PI susceptibility. Single sets allowed delineation of the impact of individual mutations on PI susceptibility, as well as the influence of PI-RAMs on one another. Comparing across sets, it could be inferred how the background influenced the interaction between two mutations, in some cases even changing antagonistic relationships into synergistic ones or vice versa. The approach elaborates on patient data and demonstrates how the specific mutational background greatly influences the impact of individual mutations on PI susceptibility in clinical patterns.
Van Marck
H
H
Tibotec BVBA, Mechelen, Belgium. hvmarck@its.jnj.com
Dierynck
I
I
Kraus
G
G
Hallenberger
S
S
Pattery
T
T
Muyldermans
G
G
Geeraert
L
L
Borozdina
L
L
Bonesteel
R
R
Aston
C
C
Shaw
E
E
Chen
Q
Q
Martinez
C
C
Koka
V
V
Lee
J
J
Chi
E
E
de Béthune
M-P
MP
Hertogs
K
K
D000595:Amino Acid Sequence; D003001:Cloning, Molecular; D019295:Computational Biology; D024882:Drug Resistance, Viral / Q000235:genetics*; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000201:enzymology / Q000502:physiology*; D006801:Humans; D009154:Mutation / Q000502:physiology*; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000235:genetics
D017320:HIV Protease Inhibitors; D010446:Peptide Fragments; D016333:HIV Protease